News
RDUS
10.11
-6.73%
-0.73
Hot Stocks: KMX, BB rise on earnings; WOLF upgrade; RDUS slips after previous day's gains
Earnings news gave a lift to a handful of stocks in Friday's midday action. CarMax (NYSE:KMX) and BlackBerry (BB) both showed strength after releasing their respective financial figures. Meanwhile, Wolfspeed
Seekingalpha · 1d ago
Radius (RDUS) to Go Private With $890M Deal, Shares Gain
Radius (RDUS) will go private following the acquisition by Gurnet Point Capital and Patient Square Capital.
Zacks · 1d ago
4 Analysts Have This to Say About Radius Health
Analysts have provided the following ratings for Radius Health (NASDAQ:RDUS) within the last quarter:
Benzinga · 1d ago
Radius (RDUS), Menarini Submit NDA for Breast Cancer Drug
Radius (RDUS) and partner The Menarini Group submit a new drug application to the FDA for elacestrant for treating patients with ER+/HER2- advanced or metastatic breast cancer.
Zacks · 2d ago
Bone Health Focused Radius Health Goes Private In $890M Deal
Benzinga · 2d ago
Sector Update: Health Care
MT Newswires · 2d ago
The Daily Biotech Pulse: F-Star Therapeutics Buyout, Orphan Drug Tag For VBI's Brain Cancer Vaccine, Xenon's Epilepsy Candidate Shows Promise
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 2d ago
Radius Health jumps 14% on $890M buyout offer
The shares of Radius Health (NASDAQ:RDUS) surged 14% in the morning hours Thursday after the commercial stage biotech announced an agreement under which y Gurnet Point Capital and Patient Square Capital will
Seekingalpha · 2d ago
BRIEF-Radius Health Announces Deal To Be Bought By Gurnet Point Capital, Patient Square Capital
BRIEF-Radius Health Announces Deal To Be Bought By Gurnet Point Capital, Patient Square Capital
Reuters · 2d ago
Radius Health Announces Agreement To Be Acquired By Gurnet Point Capital And Patient Square Capitall Says Potential Share Value Of $11, Including $10 Cash Paid At Closing And Potential $1 CVR; Total Transaction Worth ~$890M
Radius Health Announces Agreement to be Acquired by Gurnet Point Capital and Patient Square Capital Transaction delivers immediate value and liquidity to Radius shareholders   Result of nine-month strategic
Benzinga · 2d ago
Radius Health Announces Agreement to be Acquired by Gurnet Point Capital and Patient Square Capital
Transaction delivers immediate value and liquidity to Radius shareholdersResult of nine-month strategic review process by the Radius Board to maximize shareholder valuePotential per share value of $11.00, including $10.00 cash paid at closing and potential...
GlobeNewswire · 2d ago
Radius Health to Go Private in $890 Million Acquisition Deal With Gurnet Point Capital, Patient Square Capital
MT Newswires · 2d ago
Radius Health to be Acquired by Gurnet Point Capital, Patient Square Capital in $890 Million Deal; Shares Rise
MT Newswires · 2d ago
Menarini Group, Radius Health seek FDA approval for breast cancer treatment elacestrant
Italian pharma giant Menarini Group and Radius Health (NASDAQ:RDUS) on Wednesday said they had submitted a new drug application to the U.S. FDA for their drug elacestrant to treat breast cancer. RDUS'
Seekingalpha · 2d ago
Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients Priority Review requested; if accepted, anticipate an 8-month FDA review Positive EMERALD study data previously announced on
Benzinga · 3d ago
BRIEF-Menarini Group And Radius Health Submit New Drug Application To The U.S. FDA For Elacestrant
BRIEF-Menarini Group And Radius Health Submit New Drug Application To The U.S. FDA For Elacestrant
Reuters · 3d ago
Radius Health, Menarini Group File Application With US FDA for Elacestrant to Treat Certain Breast Cancer Patients
MT Newswires · 3d ago
BRIEF-Velan-Repertoire Releases Detailed Presentation On Need For Board Change At Radius Health And Sends Letter To Stockholders
BRIEF-Velan-Repertoire Releases Detailed Presentation On Need For Board Change At Radius Health And Sends Letter To Stockholders
Reuters · 4d ago
Velan-Repertoire Releases Detailed Presentation on the Need for Board Change at Radius Health and Sends Letter to Stockholders
ALPHARETTA, Ga., June 21, 2022--Velan Capital Investment Management LP and Repertoire Partners LP (together with the other participants in their solicitation, "Velan-Repertoire" or "we"), collectively one of the largest stockholders of Radius Health, Inc. ...
Business Wire · 4d ago
Radius Health gains over 10% as major investor backs board changes
The commercial-stage biotech added more than 10% Thursday after hedge fund manager and one of the company’s major shareholder Rubric Capital Management announced its support for an activist slate of board members.
Seekingalpha · 06/16 19:59
More
Webull provides a variety of real-time RDUS stock news. You can receive the latest news about Radius Health through multiple platforms. This information may help you make smarter investment decisions.
About RDUS
Radius Health, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing endocrine therapeutics. Its lead product, TYMLOS (abaloparatide) injection, is a prescription medicine for the treatment of postmenopausal women with osteoporosis at high risk for fracture. It also has products in clinical pipeline, which includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in the treatment of postmenopausal women with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group, and RAD011, a synthetic cannabidiol oral solution that is being developed for the treatment of Prader-Willi syndrome (PWS).